Mounjaro vs Zepbound

Mounjaro and Zepbound are both manufactured by Eli Lilly and contain the same active ingredient -- tirzepatide, a dual GIP/GLP-1 receptor agonist. The critical difference is their FDA-approved indication. According to FDA prescribing information, Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Zepbound is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and it received an additional approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.

Because the active ingredient is the same, the distinction between Mounjaro and Zepbound is primarily regulatory and financial rather than pharmacological. Which label a physician prescribes determines how the medication is classified for insurance purposes. A Mounjaro prescription is typically processed under a diabetes pharmacy benefit, while a Zepbound prescription is processed under a weight management or obesity benefit. Coverage, copays, and prior authorization requirements can differ substantially depending on the label and the patient's insurance plan. For patients without adequate insurance coverage for Zepbound, Eli Lilly launched a self-pay vial option through its Lilly Direct program in December 2025, offering tirzepatide at a lower out-of-pocket cost than the branded auto-injector pen.

Patients should not attempt to use one label interchangeably with the other or request a specific brand for an off-label purpose. The prescribed label should match the patient's diagnosed condition. Talk to your doctor about your diagnosis and treatment goals, and work with your insurance provider to understand your coverage options for whichever formulation is medically appropriate.